Search

Search Constraints

You searched for: Author/Creator Enei, Yuki

Search Results

1. Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high‐risk metastatic hormone‐sensitive prostate cancer. Issue 1 (24th September 2021)

2. Clear identification of the rare solitary external iliac lymph node metastasis of testicular cancer by using indocyanine green fluorescence guidance. Issue 3 (24th February 2021)

3. Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab. (6th August 2020)

4. Docetaxel versus abiraterone for metastatic hormone‐sensitive prostate cancer with focus on efficacy of sequential therapy. Issue 6 (20th January 2023)

5. Does castration status affect docetaxel‐related adverse events? :Identification of risk factors for docetaxel‐related adverse events in metastatic prostate cancer. Issue 14 (29th June 2022)

6. No survival benefit found after extended treatment with docetaxel for patients with castration‐resistant prostate cancer. Issue 14 (2nd August 2019)